Theravance Biopharma to Announce Q3 2024 Financial Results on Nov 12, 2024

Theravance Biopharma, Inc. (NASDAQ: TBPH), based in Dublin, has announced that it will release its financial results for the third quarter of 2024 and provide a business update after the market closes on Tuesday, November 12, 2024. The company will also host a conference call and webcast at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) on the same day.

Investors and interested parties can participate in the live call by pre-registering via the provided link. Additionally, the live conference call can be accessed through Theravance Biopharma's website, specifically under the Investors section in the Events and Presentations area. For those unable to attend the live session, a replay of the webcast will remain accessible on the company's website until December 12, 2024.

Theravance Biopharma, Inc. is dedicated to delivering impactful medicines that significantly improve people's lives. Over the years, the company has built considerable expertise that has resulted in the development of YUPELRI® (revefenacin) inhalation solution. This FDA-approved treatment is designed for the maintenance of patients suffering from chronic obstructive pulmonary disease (COPD).

Another notable project in Theravance Biopharma's pipeline is Ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor. This once-daily medication is being developed for treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). Ampreloxetine has the potential to become a first-in-class therapy that effectively addresses multiple cardinal symptoms experienced by MSA patients.

Theravance Biopharma remains committed to driving shareholder value through its innovative medical solutions and groundbreaking research. The company is also focused on maintaining and enhancing its reputation for excellence and leadership in the biopharmaceutical industry.

YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies in the U.S. and certain other countries. Any other trademarks, trade names, or service marks mentioned in this announcement are the property of their respective owners.